Alzheimer’s Disease Medical University of Sofia, Faculty of Medicine

Slides:

Advertisements

Similar presentations

Alzheimer’s and Parkinson’s Disease Chan, Joanna & Dorisca, Lamar.

Advertisements

Alzheimer Disease Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University

Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.

Dementia Drugs: Mainstream and Alternative Medicines Susan Kurrle.

Pathology and Treatment

Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.

Cognitive Enhancers. Dementia A syndrome due to disease of the brain, characterised by progressive, global deterioration in intellect including: Memory.

The Memory Spectrum: Is it Alzheimer’s Disease?

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.

Decision presented by the committee board members: Nicholas Mann & Katelyn Strasser FUTURE FUNDING FOR ALZHEIMER’S DISEASE October 14, 2014 MPH 543 Leadership.

ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.

Alzheimer’s Disease Angela Singh, PharmD Associate Professor of Pharmacy Practice Florida A&M University College of Pharmacy & Pharmaceutical Sciences.

ALZHEIMER’S PART 2. AD VIDEO

Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.

Pharmacological Management. Only symptomatic treatment, there is no cure. Acetylcholinesterase inhibitors - Only for mild to moderate dementia –Donepezil.

Alzheimer’s Disease Landscape

Copyright © 2007, 2003 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 37 Confusion and Dementia.

LISA JOHNSON & SUZANNE GRIESEL MPH 543 LEADERSHIP AND ORGANIZATIONAL BEHAVIOR FEBRUARY 16, 2014 Funding Analysis of Alzheimer’s Treatment Options: Three.

DEMENTIA AND ALZHEIMER'S DISEASE. IMPAIRMENT OF BRAIN FUNCTION ( DECLINE IN INTELLECTUAL FUNCTIONING) THAT INTERFERES WITH ROUTINE DAILY ACTIVITIES. MENTAL.

By: Tasso Skountzouris David Schiano. General Description  Alzheimer’s is one the most common form of Dementia  Dementia causes a loss of brain function.

Alzheimer’s Disease Causes, Effects, and Treatments.

Alzheimer disease and other mental impairments Medications for Alzheimer disease Zvereva Mila school of pharmacy.

Cristopher Ramirez Psychology Period 6. A common form of dementia, usually beginning in late middle age, characterize by memory lapses, confusion, emotional.

Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.

Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)

Heather Kellogg March 6, 2013 Honors Psychology, Period 1

COLUMBIA PRESBYTARIAN HOSPITAL CENTER

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Do you remember what you ate for dinner two days ago?

Alzheimer’s Disease By: Nora Teen Health 8 Period 1.

Alzheimer's: An Investigation into Treatment Options Dana McGuire and Jessica Scharfenberg MPH 543: Leadership and Organizational Management Concordia.

DEMENTIA ABDULMAJEED ALOLAYAH What is DEMENTIA ? It is a chronic global impairment of cognitive functions without disturbed consciousness.

Amyotrophic lateral sclerosis

Dementia Care Wendy Burnett CNS for Older People.

The Facts about Alzheimer’s Disease By: Mr. Frantz.

BY: AMAN SINGH AND ALLY MATTINGLY Alzheimer's Disease.

Marks condition: Alzheimer's Disease By: Karla Garcia Jeff Gegetskas Eriec Alvarez.

Kynnera Stephenson Lubbock Christain University \.

Alzheimer's disease 蕭尚益丁唯洋蔡欣容. Outline introductionDisease mechanismPreventConclusion.

It is a chronic neurodegenerating disease that usually starts slowly and gets worse over time.

ALZHEIMER’S DISEASE Brenden Cole.

Cognitive Development Dementia. Stages: Preclinical First sign: memory loss for the familiar First sign: memory loss for the familiar Biological changes.

COGNITIVE DEVELOPMENT IN LATE ADULTHOOD CHAPTER 18 Lecture Prepared by: Dr. M. Sawhney.

ALZHEIMER’S DISEASE AHII.

What is Alzheimer’s disease? – Causes, Symptoms & Treatment?

DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.

Alzheimer’s Disease What is Alzheimer’s Disease and what happens to the brain of someone affected by the disease?

 The rehabilitation goal for every patient with temporary or permanent cognitive impairment is to promote maximal involvement in self care and meaningful.

PARKINSON’S DISEASE LUKE CARROLL & LAUREN DESROCHES.

DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.

Dementia and Medication Considerations

Alzheimer’s: How much does it impact your Brain’s anatomy

DEMENTIA - A GENERAL TERM FOR A DECLINE IN MENTAL ABILITY,SEVEREENOUGH TO INTERFERE WITH DAILY LIVES, MEMORY LOSS IS AN EXAMPE . ALZHEIMER’S IS THE.

Neurocognitive Disorders

How Does Dementia Affect the Brain and it’s Cognitive Processes

Medications for Dementia

Erin Blackshear Amber Burks Danielle Chelette

What does this protein make up or do?

Figure 19.1 Alzheimer disease and the resulting dementia occur when changes in the brain hamper neurotransmission.

Progress Report on Alzheimer’s Disease

Diagnosing Patient #2 The two studs (you know who we are) (Zach and Jack in case you didn’t know)

Patient #2 Wilson Erwin.

Diagnosing Patient #2 The two studs (you know who we are) (Zach and Jack in case you didn’t know)

INTRODUCING 3 DISEASES THAT AFFECTS THE NERVE SYSTEM

Drugs for Degenerative Diseases of the Nervous System

PowerPoint made by: Monique Johnson

Learning and Memory Learning deficiencies and Disorders

Cholinesterase Inhibitors: Actions and Uses

DEMENTIA By: Amber Ruddock.

Presentation transcript:

Alzheimer’s Disease Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)

Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology

Background It is the progressive mental deterioration that can occur in middle or old age, due to generalized degeneration of the brain. It causes a steady loss of memory, speech, thinking, and carrying on daily activities. As a person becomes older the risk for developing Alzheimer’s increases. Annual cost can be over $50,000 Affects over 26.6 million people worldwide

Symptoms Memory loss confused about time and place changes in personality and mood trouble speaking and accomplishing tasks

7 Stages No impairment very mild cognitive decline moderate cognitive decline moderately severe cognitive decline severe cognitive decline very severe cognitive decline

Anatomical Changes Neurofibrillary tangles loss of neuronal synapse dead or dying nerve cells formation of plaques

Treatment Acetylcholine esterase inhibiters Rivastigmine Galantamine Donepezil NMDA receptor antagonist Memantine

Side Effects nausea vomiting loss of appetite headache confusion constipation(memantin e)

Behavioral Drugs Antidepressants Peroxeine Fluxetine Anxiolytics Lorazepam Antipsychotic Clozapine Haloperidol

Clinical Trials “Alzheimer’s in Long-Term Care-- Treatment for Agitation” “Cognitive Behavioral Therapy of Early Dementia” “Nefiracetam in the Treatment of Alzheimer’s Disease”

Sources www.wikipedia.com Harrison’s Internal Medicine Lippincott’s Illustrated Reviews Pharmacology NextBio Modern Pharmacology with Modern Clinical Applications http://www.alz.org/index.asp